Marine cyanobacteria—a prolific source of natural products

Marine algae are one of the largest producers of biomass in the marine environment. They produce a wide variety of chemically active metabolites in their surroundings, potentially as an aid to protect themselves against other settling organisms. These active metabolites, also known as biogenic compounds, produced by several species of marine macro- and micro-algae, have antibacterial, antialgal, antimacrofouling and antifungal properties, which are effective in the prevention of biofouling, and have other likely uses, e.g. in therapeutics. The isolated substances with potent antifouling activity belong to groups of fatty acids, lipopeptides, amides, alkaloids, terpenoids, lactones, pyrroles and steroids. These biogenic compounds have the potential to be produced commercially using metabolic engineering techniques. Therefore, isolation of biogenic compounds and determination of their structure could provide leads for future development of, for example, environmentally friendly antifouling paints. This paper mainly discusses the successes of such research, and the future applications in the context of understanding the systems biology of micro-algae and cyanobacteria.

Exploitation of marine algae: biogenic compounds for potential antifouling applications

Microalgae have found commercial applications as natural sources of valuable macromolecules, including carotenoids, long-chain polyunsaturated fatty acids, and phycocolloids. As photoautotrophs, their simple growth requirements make them attractive for bioprocesses aimed at producing high added-value compounds that are in large demand by the pharmaceutical market. A few compounds synthesized by microalgae have indeed proven to possess anti-inflammatory, antiviral, antimicrobial, and antitumoral features; astaxanthin, a known antioxidant produced by Haematococcus pluvialis, is an illustrative example with important anti-inflammatory and antitumoral roles. From a chemical standpoint, several such compounds are polysaccharides or long chain fatty acids, where the latter can be either saturated or unsaturated. Additionally, their chemical structures are often atypical, whereas their concentrations can exceed those found in many other natural sources. The productivity and biochemical composition of microalgae depend strongly on the mode of cultivation, medium composition, and nutrient profile. Consequently, numerous efforts aimed at elucidating the practical impacts of the aforementioned parameters have been developed. This review accordingly covers the knowledge produced in the last two decades on the uses of microalgae to obtain physiologically active compounds, and on the optimization of the underlying production and purification processes. It also identifies major gaps and opportunities in this field that should be addressed or exploited in the near future.

Microalgae as sources of high added-value compounds--a brief review of recent work.

Downstream processing of algal polyunsaturated fatty acids.

Pathogenic bacteria, such as multidrug-resistant Staphylococcus aureus (MRSA), which are not susceptible to most conventional antibiotics, are causing increased concern in healthcare institutions worldwide. The discovery of novel antibacterial compounds for biomedical exploitation is one avenue that is being pursued to combat these problematic bacteria. Marine eukaryotic microalgae are known to produce numerous useful products but have attracted little attention in the search for novel antibiotic compounds. Cell lysates of the marine diatom, Phaeodactylum tricornutum Bohlin, have been reported to display antibacterial activity in vitro, but the compounds responsible have not been fully identified. In this paper, using column chromatography and reversed-phase high-performance liquid chromatography, we report the isolation of an antibacterial fatty acid. Mass spectrometry and 1H-nuclear magnetic resonance spectroscopy revealed it to be the polyunsaturated fatty acid, eicosapentaenoic acid (EPA). We show that EPA is active against a range of both Gram-positive and Gram-negative bacteria, including MRSA, at micromolar concentrations. These data indicate that it could find application in the topical and systemic treatment of drug-resistant bacterial infections.

A fatty acid from the diatom Phaeodactylum tricornutum is antibacterial against diverse bacteria including multi-resistant Staphylococcus aureus (MRSA).

Masaomi Kondo

Papers

Anti methicillin-resistant Staphylococcus aureus (MRSA) activity by linolenic acid isolated from the marine microalga Chlorococcum HS-101

Antibiotic substance produced by a newly isolated marine microalga, Chlorococcum HS-101

Sustained production of arachidonic and eicosapentaenoic acids by the red alga Porphyridium purpureum cultured in a light/dark cycle